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Background/aim: This study represents the first report that evaluates the experience gathered from diagnosis, surgical treatment and
outcome of insulinoma patients from Azerbaijan.
Materials and methods: We retrospectively review of insulinoma patients for a 10-year period. Collected data included patient
demographics, laboratory and imaging tests, detailed surgical reports, histopathological examination of resected specimens, and clinical
follow-up.
Results: Twenty-one insulinoma patients were identified. Male patients comprised 52.4%; mean age was 44 years. Mean time to diagnosis
was 14 months; 61% patients had ≥3 medical referrals due to hypoglycemia-related symptoms. Diagnosis sensitivity of CT, MRI and US
was 85%, 80%, and 55%, respectively. The mean glucose, insulin, C-peptide levels were 35.7 ± 9.5 mg/dL, 33.5 ± 21.9 µU/mL, and 3.74
± 1.88 ng/mL, respectively. Pancreatic head and tail were the most frequent tumor locations; mean tumor size was 1.5 ± 0.7 cm. No
statistical association was found between the tumor size and preoperative glucose, C-peptide and insulin levels. Distal pancreatectomy
and enucleation were the most common surgical procedures. Local tumor recurrence rate was 14%. There was no mortality.
Conclusions: To prevent delayed diagnoses, physicians should be familiar with the typical symptoms of these rare tumors.
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1. Introduction
Insulinomas are rare pancreatic neuroendocrine tumors
(PanNET), which are found in 1–4 per million people
each year [1,2]. Although PanNet account for less than
3% of all pancreatic tumors, their incidence had increased
in the past two decades due to the advances in tumor
localization capabilities [3,4]. PanNET can be functional
or nonfunctional tumors depending on the presence of
symptoms associated with hormone overproduction [5].
The most common functional PanNET is characterized
by excessive amounts of insulin secreted [6]. Classically,
these patients present with the Whipple’s triad, consisted
of (a) hypoglycemic symptoms, (b) hypoglycemia (blood
glucose level <50 mg/dL), and (c) relief of symptoms
following administration of glucose. Patients may also
present with muscle cramps, neuroglycopenic symptoms
such as syncope, confusion, dizziness, and adrenergic
symptoms such as tremor and tachycardia. Despite the

classical symptoms, diagnosis of these tumors is often
delayed in clinical practice. Surgical treatment strategies
involve enucleation and resection of the tumor, although
percutaneous ablation of lesions not amenable to surgery
or chemotherapy for metastatic disease are also included
[6,7].
Report of case series are mostly retrospective in nature
and critical for rapidly developing and transitioning
countries such as Azerbaijan for future comparisons. The
aim of this study is to report the experience on PanNET at
Azerbaijan Medical University.
2. Material and methods
This is a retrospective case series study approved by the
Azerbaijan Medical University Ethical Committee (6
September 2018/C0234). Patients who underwent surgery
at the Azerbaijan Medical University between March 2007
and April 2017 and had histopathological diagnosis of

* Correspondence: patrizio.petrone@nyulangone.org

1262

This work is licensed under a Creative Commons Attribution 4.0 International License.

HASANOV et al. / Turk J Med Sci
insulinoma were included in the study. Medical records
of these patients were reviewed for data that include
demographics, elapsed time between symptoms onset and
diagnoses, location and size of insulinomas, diagnostic
imaging methods, surgical reports, histopathological
examination reports of resected specimens, postoperative
complications for descriptive purposes.
Data showed that all patients had a 72-h fast test for
diagnosing insulinoma. During the test, upon finding
a plasma glucose level of less than 45 mg/dL and
hypoglycemia symptoms and findings, blood samples for
plasma glucose, insulin and C-peptid levels were taken.
The biochemical diagnosis of insulinoma was established
during prolonged fasting (up to 72 h) when the following
results were found: insulin level >3.0 µU/mL (18 pmol/L),
C-peptid level >0.6 ng/mL (0.2 nmol/L), and plasma
glucose level <45 mg/dL.
The abovementioned tests were followed by imaging
tests to visualize the pancreas. Localization tests that
include transabdominal ultrasound (US), computed
tomography (CT), magnetic resonance imaging (MRI),
arterial calcium stimulation and venous sampling
(ASVS) and In-111 octreotide scintigraphy were also
documented [8]. The palpation of whole pancreatic gland
was also deemed helpful by the authors of this study,
which occasionally was accompanied by intraoperative
ultrasonography upon suspicious findings.
The choice of surgery depended on the location and
size of the tumor. Superficial and encapsulated tumors
were enucleated. Pancreatectomy was performed in cases
with neck and proximal body insulinomas situated deep
in the pancreatic gland and/or tumor location in close
proximity to the main pancreatic duct. Extent and type of
the resection was up to the surgeons’ choice. Pancreatic
fistulas were classified according to the Study Group on
Pancreatic Fistula grading [9].
Pathological examination of specimens was performed
using conventional histologic and immunohistochemical
(chromogranin A and synaptophysin) techniques. Ki67
index was expressed as a percentage of Ki67-positive cells
in 2000 tumor cells.
Follow-up data was gathered from outpatient
records. Patients were examined clinically; laboratory
and radiological tests were performed annually during
the follow-up. Postoperative diagnosis/treatment of
diabetes and pancreatic enzyme replacement therapy were
performed by the endocrinology and gastroenterology
clinics, respectively.
2.1. Statistical analysis
Continuous data were expressed as mean ± standard
deviation (SD). Categorical data were reported as
frequencies. Association between dichotomous and
continuous data was analyzed using point-biserial

correlation test; in order to perform Pearson’s correlation
test, either normality of the data should be checked, or
nonparametric Spearman’s test should be preferred. Group
differences with continuous data were analyzed using
independent samples t test. Data were statistically analyzed
using SPSS version 22.0 software (IBM Inc.; Armonk, NY,
USA). Statistical significance was set at <0.05.
3. Results
Medical charts of patients diagnosed with insulinoma were
retrospectively identified, and analyzed at the Azerbaijan
Medical University. Twenty-one patients were included
in the study. The majority (52.4%) of patients were male.
The mean age was 44.2 ± 17.2 year-old and the mean time
from symptoms onset to diagnosis was 14 ± 13.9 months
(Table 1). Out of 21 patients, 17 (80%) had a history of at
least one referral, while 13 (61%) patients had ≥ 3 referrals
to various medical facilities due to complaints related
to hypoglycemia. Neurology was the most commonly
referred clinic. Whipple’s triad was present in all patients
at the time of admission. The mean glucose, insulin,
C-peptide levels at admission were 35.7 ± 9.5 mg/dL, 33.5
± 21.9 µU/mL, and 3.74 ± 1.88 ng/mL, respectively. The
most common symptoms during admission were syncope
(76%), sweating (65%), and palpitation (41%).
US, CT, and MRI were the most frequently preferred
imaging techniques used. In order to localize the tumor,
In-111 octreotide scintigraphy was performed in two
(9.5%) patients and ASVS was used in three (14.2%).
The sensitivity of CT, MRI and US was 85% (12/14), 80%
(12/15), and 55% (6/11), respectively (Figures 1 and 2).
Pancreatic head and tail were the most frequent
location of the tumors that comprised eight (38%) and
seven (33.3%) patients, respectively (Table 2). Macroscopic
examination of the resected specimens showed that
the mean tumor diameter was 1.5 ± 0.7 cm. There was
no correlation between tumor size and parameters of
preoperative glucose, C-peptide and insulin levels (P >
0.05).
During the laparotomy, the operating surgeon
suspected the presence of multiple pancreatic tumor in two
(9.5%) patients, which was confirmed by intraoperative
ultrasonography. The ultrasound also revealed that the
tumors were in close relationship with the main pancreatic
duct (< 2 mm). Thus, the decision was to perform a total
pancreatectomy. Multiple endocrine neoplasia (MEN-1
syndrome) was diagnosed in one of these patients. Distal
pancreatectomy was performed in eight cases (38%),
enucleation in and six (28.7%), Whipple procedure in four
(19%), total pancreatectomy in two (9.5%), and segmental
pancreatectomy in one (4.7%) case (Table 2) (Figures 3
and 4).
During the median 36-month follow-up period (range:
3–60 months), local tumor recurrence was found in three
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Table 1. Demographic data of insulinoma patients.

a
b

Number of patients: n (%)

Male: 11 (52.4)
Female: 10 (47.6)

Age (Mean ± SD)

Overall: 44.2 ± 17.2 years
Female: 41.2 ± 20a years
Male: 46.9 ± 14.5a years

Time from onset of symptoms to diagnosis (Mean ± SD)

Overall: 14 ±13.9 months
Female: 13.8 ±11.5b months
Male: 15.09 ±16.6b months

Biochemical tests to confirm insulinoma (Mean ± SD)

Insulin level: 33.5 ± 21.9 µU/mL
C-peptid: 3.74 ± 1.88 ng/mL
Glucose: 35.7 ± 9.5 mg/dL

Frequency of symptoms at admission (%)

Syncope (76)
Sweating (65)
Tachycardia (41)
Tremor (35)
Vertigo (29)
Sleep disorder (24)
Weight gain (24)

Group differences were not statistically significant (P = 0.46).
Group differences were not statistically significant (P = 0.83).

A

B

Figure 1. (A) MRI (T2A) images of the abdomen. Arrow shows
the hyperintense insulinoma in the pancreatic head. (B) Arterial
phase CT image of the abdomen. Arrow shows hypervascular,
hyperdense mass lesion in the pancreatic tail.
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(14.2%) male patients (Table 3). Two (9.5%) patients
presented with metastatic lymphadenopathy close to the
resection margin, which was located by CT imaging. These
two patients underwent radical lymphadenectomy and
received adjuvant chemotherapy. A Whipple procedure was
initially performed on one of these patients and a second
tumor appeared close to the resection site. The patient
underwent total pancreatectomy, lymphadenectomy, and
adjuvant chemotherapy. None of these patients presented
with hepatic metastases.
Although laparoscopic cancer surgery has been steadily
increasing in Azerbaijan, only two (9.5%) insulinoma
patients were operated laparoscopically. Enucleation of
insulinoma from the pancreatic head was performed in one
patient, while the other underwent a laparoscopic spleenpreserving distal pancreatectomy due to an insulinoma in
the pancreatic tail.
Complete resolution of hypoglycemic symptoms
and clinical improvement was achieved in all patients
postoperatively. Two total pancreatectomy and one distal
pancreatectomy patients became diabetic (14.2%) in the
early postoperative period. New onset malabsorption that
required enzyme replacement therapy was also found in
these three (14.2%) patients. There was no perioperative or
postoperative mortality. The mean length of stay was 13.4
± 8.2 days. The most common postoperative complication
was ‘biochemical leak’ from the pancreas, which occurred
in four (19%) patients. Two (9.5%) cases were due to
enucleation and the other two (9.5%) occurred after
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Figure 2. CT-angio image of insulinoma in the pancreatic tail (posterior view).Tumor
size is shown.
Table 2. Location of resected insulinomas and surgical
procedures performed.
Location:
n (%)

Surgical procedures:
n (%)

Head			9 (42.8)
Tail			7 (33.3)
Body			4 (19)
Neck			1 (4.7)
Distal pancreatectomy
Enucleation		
Whipple procedure		
Total pancreatectomy
Segmental pancreatectomy

8 (38)
6 (28.7)
4 (19)
2 (9.5)
1 (4.7)

Whipple procedures. These patients required prolonged
use of intraabdominal drains. Surgical site infections were
diagnosed in three (14.2%) patients, which was treated
by partial removal of surgical sutures, frequent dressing
changes and tertiary wound closure.
4. Discussion
Although insulinomas are a rare disease, they are the most
commonly diagnosed type of functional PanNET. Most
cases reported in the literature are either case reports,
case series or reviews [10–17]. Despite the nonspecificity
of its symptoms, typical severe fasting hypoglycemia in
nondiabetics and presence of Whipple triad should suggest
a possible diagnosis of insulinoma, even may present
with postprandial severe hypoglycemia [18]. Failure to
recognize these symptoms may lead to delays in diagnosis.

Our data showed that the mean symptoms from onset to
diagnosis was 14 months and 80% of patients had sought
previous medical attention.
Sporadic insulinomas have been reported to occur
‘anytime in life’, they seem to affect both genders equally,
and the mean age at presentation is 47 years [19]. Similarly,
we report a mean age of 44 years (range: 21–80). Overall,
90.5% of cases had solitary pancreatic tumors in our
series and except for the case associated with MEN-1
syndrome, 95% of sporadic insulinomas had solitary
tumors. Likewise, literature data shows that approximately
90% of insulinomas are sporadic, and tend to be solitary
and treatable by limited resection [20]. Although literature
shows that insulinomas may be located anywhere in the
pancreas, the majority of tumors have been reported to
be located in the body and tail and their sizes are smaller
than 2 cm, whereas malignant tumors are usually over 3
cm in diameter [20–23]. Our report showed that 76.1% of
insulinomas were located in the head and tail of pancreas
and the mean tumor size was 1.5 cm. Interestingly, the
recurrent tumor size in our study was 1.4 cm.
Imaging techniques, including intraoperative
ultrasound, are critical for planning the most appropriate
surgical procedure. Dynamic CT has replaced conventional
CT technique due to its ability to detect smaller tumors,
which increase the sensitivity of CT to 80%. CT also
may exclude the presence of metastases [6]. Combining
biphasic helical CT and endoscopic US has been reported
to demonstrate 100% sensitivity in localizing insulinomas
[24]. Literature data also show that MRI is important for
the detection of small diameter insulinomas that were not
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Figure 3. (A) Intraoperative view of pancreatic head after enucleation performed
and hemostasis achieved. (B) Enucleated tumor.

detected by transabdominal US or CT [6,25,26]. Octreotide
scintigraphy is of limited use in sporadic insulinomas,
its sensitivity is approximately 40%–50%.6 Although it is
an invasive procedure with potential for complications,
ASVS is especially important when other imaging
techniques fail to identify insulinomas [6]. In our series,
the sensitivity for localizing pancreatic tumors of CT, MRI
and US was 85%, 80%, and 55%, respectively. Our series
showed that the sensitivity of ASVS was 100% when other
imaging techniques failed to identify insulinomas. Tactile
information revealed that by palpating the pancreatic gland
might be helpful for tumor localization during surgery.
Moreover, intraoperative Doppler US was particularly
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helpful and accurate for detecting multiple insulinomas in
our series. Doppler US also reveals the hypervascularity of
the tumor, which is suggestive for insulinomas [12].
Crippa et al. reported [24] on the surgical management
of insulinomas bring perspective to our understanding
for tumor recurrences. They reported that positive tumor
margins were found in 4.5% of their enucleation cases.
Moreover, no lymph nodes were excised in 87%, 75%,
and 70% of enucleation, middle pancreatectomy and
spleen preserving distal pancreatectomy operations,
respectively. Likewise, in the follow-up period, two
patients (9.5%) presented with metastatic lymph nodes
after the initial resections, which may be due to the low
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Figure 4. Histopathological examination of insulinoma. (A) Solid proliferation of monomorphic cells with large cytoplasm and
round nuclei. Immunohistochemical analysis showed (B) chromogranin stained cells, (C) synaptophysin positive stained cells. The
cells were also CD56 positive. Ki67 proliferation index was 4%–5% in tumor cells.
Table 3. Details of the cases with local recurrence.
Preoperative
tumor location

Tumor
size (cm)

Surgical
procedure

Pancreatic
recurrence

Lymph node
metastasis

Tail*

0.8

Total pancreatectomy

-

+

Neck

1.6

Whipple procedure

+

+

Head

1.8

Whipple procedure

-

+

* Multiple tumors were found intraoperatively.

lymph node yield of routinely performed insulinoma
surgeries. We also advocate for Crippa et al. findings
that suggest peripancreatic lymph node sampling during
routine insulinoma surgeries in order to decrease local
recurrences. We also speculate that this may be generalized
to other PanNET surgeries. One patient presented with a
second tumor close to the resection site, and it was likely a

second primary tumor that was found at 36 months after
the initial surgery.
There were no mortalities in our series. Pancreatic
fistula has been reported to constitute the majority of
complications (3%–60%) after pancreatic resections [9].
In our series, 19% of patients presented with low grade,
‘biochemical leaks’, that required prolonged presence of
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intraabdominal suction drains. Intraoperative US and
endoscopic US may help determine the relationship
between insulinoma and pancreatic duct before proceeding
with enucleation.
This study is not without limitations. Prospective study
design for insulinomas is not practical as they are not a
frequent disease. Retrospective design inevitably led to
data constraints that led to unanswered questions. Tumor
stage and grade data were not uniformly present in patient
records. We were also unable to find any admissions that
presented with metastatic insulinomas. This is the result
that this study is a single center report and a comprehensive
database does not exist yet. As the population included in
the study is small, statistical analyses were not suitable in
many instances and results need cautious interpretation.

One interesting example is the lack of any association
between tumor size, plasma C-peptide, and insulin
levels. Moreover, as neither 5- nor 10-year follow-up of
the patients have been finished, we are unable to present
relevant survival data.
In conclusion, surgery is still the treatment of choice
for insulinomas. Unfortunately, delays in diagnosis still
occur and treating physicians should suspect insulinoma
diagnosis when typical symptoms are encountered.
Laparoscopic enucleation and pancreatic resection will
likely dominate the future surgical treatments of this
disease. However, implementation of laparoscopic surgery
seems to require the availability of endoscopic US in
order to elucidate multiple, undetected tumors and their
relationship with the main pancreatic duct.
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